Structures of PKA-phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy

  1. Juan Qin
  2. Jingfeng Zhang
  3. Lianyun Lin
  4. Omid Haji-Ghassemi
  5. Zhi Lin
  6. Kenneth J Woycechowsky
  7. Filip Van Petegem
  8. Yan Zhang  Is a corresponding author
  9. Zhiguang Yuchi  Is a corresponding author
  1. Tianjin University, China
  2. Chinese Academy of Sciences, China
  3. University of British Columbia, Canada

Abstract

Several mutations identified in phospholamban (PLN) have been linked to familial dilated cardiomyopathy (DCM) and heart failure, yet the underlying molecular mechanism remains controversial. PLN interacts with sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) and regulates calcium uptake, which is modulated by the protein kinase A (PKA)-dependent phosphorylation of PLN during the fight-or-flight response. Here, we present the crystal structures of the catalytic domain of mouse PKA in complex with wild-type and DCM-mutant PLNs. Our structures, combined with the results from other biophysical and biochemical assays, reveal a common disease mechanism: the mutations in PLN reduce its phosphorylation level by changing its conformation and weakening its interactions with PKA. In addition, we demonstrate that another more ubiquitous SERCA-regulatory peptide, called another-regulin (ALN), shares a similar mechanism mediated by PKA in regulating SERCA activity.

Data availability

Diffraction data have been deposited in PDB under the accession code: PKAc-WT PLN (PDB 7E0Z); PKAc-PLN R9C (PDB 7E11); PKAc-PLN A11E (PDB 7E12).

The following data sets were generated

Article and author information

Author details

  1. Juan Qin

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Jingfeng Zhang

    Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Lianyun Lin

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Omid Haji-Ghassemi

    Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada
    Competing interests
    The authors declare that no competing interests exist.
  5. Zhi Lin

    School of Life Sciences, Tianjin University, Tianjin, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Kenneth J Woycechowsky

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Filip Van Petegem

    Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada
    Competing interests
    The authors declare that no competing interests exist.
  8. Yan Zhang

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    For correspondence
    yan.zhang@tju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
  9. Zhiguang Yuchi

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    For correspondence
    yuchi@tju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2595-9106

Funding

National Natural Science Foundation of China (32022073)

  • Zhiguang Yuchi

National Natural Science Foundation of China (31972287)

  • Zhiguang Yuchi

Natural Science Foundation of Tianjin City (19JCYBJC24500)

  • Zhiguang Yuchi

Canadian Institutes of Health Research (PJT-159601)

  • Filip Van Petegem

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Qin et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Juan Qin
  2. Jingfeng Zhang
  3. Lianyun Lin
  4. Omid Haji-Ghassemi
  5. Zhi Lin
  6. Kenneth J Woycechowsky
  7. Filip Van Petegem
  8. Yan Zhang
  9. Zhiguang Yuchi
(2022)
Structures of PKA-phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy
eLife 11:e75346.
https://doi.org/10.7554/eLife.75346

Share this article

https://doi.org/10.7554/eLife.75346

Further reading

    1. Biochemistry and Chemical Biology
    Gabriella O Estevam, Edmond Linossi ... James S Fraser
    Research Article

    Mutations in the kinase and juxtamembrane domains of the MET Receptor Tyrosine Kinase are responsible for oncogenesis in various cancers and can drive resistance to MET-directed treatments. Determining the most effective inhibitor for each mutational profile is a major challenge for MET-driven cancer treatment in precision medicine. Here, we used a deep mutational scan (DMS) of ~5764 MET kinase domain variants to profile the growth of each mutation against a panel of 11 inhibitors that are reported to target the MET kinase domain. We validate previously identified resistance mutations, pinpoint common resistance sites across type I, type II, and type I ½ inhibitors, unveil unique resistance and sensitizing mutations for each inhibitor, and verify non-cross-resistant sensitivities for type I and type II inhibitor pairs. We augment a protein language model with biophysical and chemical features to improve the predictive performance for inhibitor-treated datasets. Together, our study demonstrates a pooled experimental pipeline for identifying resistance mutations, provides a reference dictionary for mutations that are sensitized to specific therapies, and offers insights for future drug development.

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Kira Breunig, Xuifen Lei ... Luiz O Penalva
    Research Article

    RNA binding proteins (RBPs) containing intrinsically disordered regions (IDRs) are present in diverse molecular complexes where they function as dynamic regulators. Their characteristics promote liquid-liquid phase separation (LLPS) and the formation of membraneless organelles such as stress granules and nucleoli. IDR-RBPs are particularly relevant in the nervous system and their dysfunction is associated with neurodegenerative diseases and brain tumor development. Serpine1 mRNA-binding protein 1 (SERBP1) is a unique member of this group, being mostly disordered and lacking canonical RNA-binding domains. We defined SERBP1’s interactome, uncovered novel roles in splicing, cell division and ribosomal biogenesis, and showed its participation in pathological stress granules and Tau aggregates in Alzheimer’s brains. SERBP1 preferentially interacts with other G-quadruplex (G4) binders, implicated in different stages of gene expression, suggesting that G4 binding is a critical component of SERBP1 function in different settings. Similarly, we identified important associations between SERBP1 and PARP1/polyADP-ribosylation (PARylation). SERBP1 interacts with PARP1 and its associated factors and influences PARylation. Moreover, protein complexes in which SERBP1 participates contain mostly PARylated proteins and PAR binders. Based on these results, we propose a feedback regulatory model in which SERBP1 influences PARP1 function and PARylation, while PARylation modulates SERBP1 functions and participation in regulatory complexes.